Home Tags Alzheimer’s Disease

Alzheimer’s Disease Related Content

Alzheimer’s Disease is the most common cause of dementia. Dementia describing a specific set of symptoms such as memory loss, difficulties with problem-solving, language or simply thinking. As the disease progresses, proteins build up in the brain to form structures called ‘plaques’. Eventually there is a break between the nerve cells resulting the death of the cells and a loss of brain tissue. ending in a lack of motor skills. Although progression can vary, typically after diagnosis life expectancy is around three to nine years. Fewer than 3% of people live more than fourteen years.

Management

medications, psychological intervention and care-giving are all available to AD patients. there are currently 5 different medications on offer for AD each have different results and side affects.

public health response

Public health response to dementia

Chris Lynch, Deputy CEO at Alzheimer’s Disease International, sheds light on the WHO Global action plan on the public health response to dementia 2017-2025.
future of neuroscience

Investing in the future of neuroscience

Nina Schor, Deputy Director and Acting Scientific Director of NINDS, underlines the importance of investing in the future of neuroscience.
keto diet

Keto diet risk to pregnant women and kidney disease patients

New analysis of ketogenic (keto) diets discovers health risks, including cancer, to pregnant women and patients with kidney disease.
Estrogen

Estrogen is thought to increase the risk of Alzheimer’s disease in women

Estrogen is thought to play a role in a woman's risk of developing Alzheimer's disease (AD), according to a new study.
cure for neurological disorders, non-invasive method

Indiana team explores nanoparticle cure for neurological disorders

Indiana University School of Medicine researchers are attempting to use magnetic nanoparticles to develop a cure for neurological disorders from epilepsy to Alzheimer's - without any invasive or genetic treatment.
alzheimer’s and parkinson’s diseases

JPND: Enabling collaborative research in Alzheimer’s and Parkinson’s diseases

Professor of Neurology Thomas Gasser, JPND’s Scientific Advisory Board Chair and Director of the Department of Neurodegenerative Diseases, shares in an interview JPND’s innovative research and collaboration efforts in the universal race against Alzheimer’s and Parkinson’s diseases.
developing Alzheimer’s disease

Precision medicine in action: Alzheimer’s disease & polygenic risk scores

Earlier this year, Yourgene Health entered into a collaboration with Cytox to run their genoSCORE-LAB assay in our laboratory. genoSCORE-LAB™ is a new non-invasive test that can predict the risk of an individual developing Alzheimer’s disease from a simple saliva sample.
paths to dementia

Understanding the many possible paths to dementia

Dr Roderick Corriveau, PhD from the National Institute of Neurological Disorders & Stroke, part of the National Institutes of Health in the U.S., details the importance of understanding the many possible paths to dementia.
fight dementia

Bilingualism to fight dementia

Neil Wright, on behalf of McGowan Transcriptions UK, discusses the benefits of bilingualism, specifically concerning how speaking more than one language can fight dementia.
priority for the covid-19 vaccine

Dementia patients should be given priority for the COVID-19 vaccine

Alzheimer Europe has issued a call for people with dementia and their carers to be given priority for the COVID-19 vaccine.
vascular dementia

Causes and progression of vascular dementia

Helen Green, Dementia Specialist Nurse on Dementia UK’s Admiral Nurse Dementia Helpline, charts the causes and progression of vascular dementia.
social care system

Why a reformed social care system in the UK cannot wait

Fiona Carragher, Director of Research and Influencing at Alzheimer’s Society walks us through why a reformed social care system in the UK cannot wait.
Dementia research in the UK

Dementia research in the UK and COVID-19

Samantha Benham-Hermetz, Director of Policy and Public Affairs at Alzheimer’s Research UK charts us through the priorities for dementia research in the UK in light of COVID-19.
dementia tech

Dementia Tech: Overcoming barriers to innovation post-pandemic

Daniel Berman from Nesta Challenges and Colin Capper at the Alzheimer’s Society focus here on dementia tech, including comment on overcoming barriers to innovation post-pandemic.
people with dementia, research

Why do people with dementia often go missing?

New research by the University of East Anglia found that 70% of people with dementia go missing - but why? 
early signs of dementia, mapping

Scientists propose new strategy to identify early signs of dementia

A new 'white matter lesion' mapping tool can find early signs of dementia, with more than 70% accuracy in measuring mental decline.
Neurodegenerative disease research

JPND: The largest global collaborative initiative for neurodegenerative disease research

Chairman for the global initiative EU Joint Programme – Neurodegenerative Disease Research (JPND) Professor Philippe Amouyel brings to light their innovative work in neurodegenerative disease research.
alzheimer’s disease

Alzheimer’s disease: Incurable but preventable?

Jonathan Baker of, GBS Clinic, sheds light on the current extent of our knowledge of Alzheimer’s disease.
blood test Alzheimer's

New blood test could improve detection of Alzheimer’s

A new blood test shows promise in detecting Alzheimer’s as early as 20 years before the onset of cognitive impairment, according to researchers.
racial discrimination

Racial discrimination impacts cognitive function in African-American women

Researchers from Boston University, have found that incidents of racial discrimination are associated with lower subjective cognitive function (SCF) among African-American women.

Follow Open Access Government